[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Oric Pharmaceuticals Inc (ORIC)

Oric Pharmaceuticals Inc (ORIC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 890,255
  • Shares Outstanding, K 103,518
  • Annual Sales, $ 0 K
  • Annual Income, $ -129,470 K
  • EBIT $ -150 M
  • EBITDA $ -151 M
  • 60-Month Beta 1.11
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.20

Options Overview Details

View History
  • Implied Volatility 193.00% (-55.31%)
  • Historical Volatility 75.22%
  • IV Percentile 65%
  • IV Rank 33.49%
  • IV High 436.15% on 02/05/26
  • IV Low 70.57% on 08/27/25
  • Expected Move (DTE 35) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.71
  • Today's Volume 36
  • Volume Avg (30-Day) 221
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 10,190
  • Open Int (30-Day) 9,365
  • Expected Range 8.34 to 8.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.36
  • Number of Estimates 5
  • High Estimate $-0.34
  • Low Estimate $-0.39
  • Prior Year $-0.47
  • Growth Rate Est. (year over year) +23.40%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.24 +1.21%
on 05/14/26
11.16 -25.27%
on 04/20/26
-2.19 (-20.80%)
since 04/14/26
3-Month
7.23 +15.35%
on 04/02/26
14.25 -41.47%
on 02/25/26
-1.65 (-16.52%)
since 02/13/26
52-Week
4.53 +83.90%
on 05/15/25
14.93 -44.14%
on 10/07/25
+3.48 (+71.43%)
since 05/14/25

Most Recent Stories

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

NEW YORK , May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. ("Oric" or the "Company") (NASDAQ: ORIC). Such investors are advised...

ORIC : 8.34 (-3.02%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

NEW YORK , May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc.  ("Oric" or the "Company") (NASDAQ: ORIC).  Such investors are...

ORIC : 8.34 (-3.02%)
ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates

Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 global registrational trial in post-abiraterone mCRPC, expected to initiate in 1H 2026 Reported rinzimetostat...

ORIC : 8.34 (-3.02%)
Oric's Rinzimetostat Data Suggests Pfizer Already Won the Prostate Cancer Race—Or Did It?

Barchart Research What to Expect from ORIC Earnings ORIC Generated May 1, 2026 Current Price $9.77 EPS Estimate $$-0.31 Consensus Rating Strong Buy Average Move 5.06% Oric's Rinzimetostat Data Suggests...

ORIC : 8.34 (-3.02%)
Oric's Rinzimetostat Data Suggests Pfizer Already Won the Prostate Cancer Race—Or Did It?

Barchart Research What to Expect from ORIC Earnings ORIC Generated May 1, 2026 Current Price $9.77 EPS Estimate $$-0.31 Consensus Rating Strong Buy Average Move 5.06% Oric's Rinzimetostat Data Suggests...

ORIC : 8.34 (-3.02%)
Oric's Rinzimetostat Data Suggests Pfizer Already Won the Prostate Cancer Race—Or Did It?

Barchart Research What to Expect from ORIC Earnings ORIC Generated May 1, 2026 Current Price $9.77 EPS Estimate $$-0.31 Consensus Rating Strong Buy Average Move 5.06% Oric's Rinzimetostat Data Suggests...

ORIC : 8.34 (-3.02%)
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms...

ORIC : 8.34 (-3.02%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

NEW YORK , April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. ("Oric" or the "Company") (NASDAQ: ORIC).  Such investors are...

ORIC : 8.34 (-3.02%)
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...

ORIC : 8.34 (-3.02%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

NEW YORK , April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. ("Oric" or the "Company") (NASDAQ: ORIC).  Such investors are...

ORIC : 8.34 (-3.02%)

Business Summary

ORIC Pharmaceuticals Inc. is a clinical stage oncology company. It is focused on developing treatments which address mechanisms of therapeutic resistance. The company's product candidate consists of ORIC-101 and ORIC-533 which are in clinical stage. ORIC Pharmaceuticals Inc. is based in San Francisco,...

See More

Key Turning Points

3rd Resistance Point 9.19
2nd Resistance Point 8.98
1st Resistance Point 8.66
Last Price 8.34
1st Support Level 8.13
2nd Support Level 7.92
3rd Support Level 7.60

See More

52-Week High 14.93
Fibonacci 61.8% 10.96
Fibonacci 50% 9.73
Fibonacci 38.2% 8.51
Last Price 8.34
52-Week Low 4.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.